Residency · Residency · Gastroenterology

Clostridioides difficile Infection

Microbiology and Epidemiology

Organism

Clostridioides difficile, reclassified from Clostridium in 2016, is an anaerobic, gram-positive, spore-forming bacillus. Its spores are resistant to heat, acid, and alcohol-based hand sanitizers, can persist on environmental surfaces for months, and require bleach-based or sporicidal disinfection for eradication. Toxigenic strains produce toxin A (TcdA, an enterotoxin) and toxin B (TcdB, a cytotoxin), both of which cause direct mucosal damage. A subset of strains also produces binary toxin (CDT), an additional virulence factor associated with worse clinical outcomes. The NAP1/BI/027 hypervirulent epidemic strain (ribotype 027) produces higher levels of both toxins and binary toxin, is fluoroquinolone-resistant, and is associated with more severe disease, higher recurrence rates, and community-acquired infection.

Epidemiology

C. difficile infection is the most common healthcare-associated infection in the United States, with approximately 500,000 cases and 29,000 deaths annually. Community-acquired CDI represents an increasing proportion of cases (30 to 40%), affecting younger patients with fewer traditional risk factors. The recurrence rate is 15 to 25% after the first episode and escalates dramatically to 40 to 65% after the second episode.

Risk Factors

Antibiotic exposure is the single most important risk factor, with the highest risk conferred by fluoroquinolones, clindamycin, cephalosporins, and carbapenems. The risk persists for 3 months after exposure, and even single-dose surgical prophylaxis can increase susceptibility. Hospitalization and healthcare exposure, particularly long-term care facilities and intensive care units, represent major risk factors. Age over 65 is associated with reduced humoral immune response to C. difficile toxins. PPI use has a modest association (odds ratio 1.3 to 2.0), though this relationship remains controversial, and PPIs should not be discontinued solely for CDI prevention. Immunosuppression from chemotherapy, solid organ transplantation, or IBD therapies increases risk. IBD itself confers a 2- to 3-fold increased risk with more severe outcomes.

Pathogenesis

The pathogenesis of CDI begins with disruption of the normal colonic microbiota (dysbiosis), which creates an ecological niche for C. difficile colonization. Ingested spores germinate in the colon in a bile acid-dependent process, giving rise to vegetative cells that produce toxins A and B. These toxins are glucosyltransferases that inactivate Rho GTPases within colonocytes, disrupting the actin cytoskeleton, causing loss of tight junction integrity, mucosal damage, fluid secretion, and neutrophil recruitment. Pseudomembranes, the hallmark endoscopic finding, are composed of yellow-white plaques of fibrin, neutrophils, and cellular debris overlying denuded epithelium. The host immune response, specifically anti-toxin IgG antibodies (particularly anti-TcdB), correlates with protection from recurrence and forms the rationale for bezlotoxumab therapy.

Clinical Presentation

Spectrum of Disease

The clinical spectrum of CDI ranges widely. Asymptomatic colonization occurs in 3 to 7% of hospitalized adults and is higher in long-term care settings; these patients should not be tested or treated. Non-severe CDI presents with watery diarrhea (3 or more unformed stools per 24 hours), lower abdominal cramping, and low-grade fever, with white blood cell count below 15,000 and creatinine below 1.5. Severe CDI is defined by a white blood cell count of 15,000 or greater or serum creatinine of 1.5 mg/dL or greater. Fulminant CDI, formerly termed severe-complicated, manifests with hypotension or shock, ileus, or toxic megacolon, and may present paradoxically with ileus and the absence of diarrhea (obstipation). Pseudomembranous colitis is the classic endoscopic finding, though its absence does not exclude the diagnosis.

Diagnosis

Testing Algorithm (ACG/IDSA Multistep)

The approach to CDI diagnosis must begin with appropriate patient selection: testing should only be performed on patients with 3 or more unformed stools in 24 hours or new-onset ileus with clinical suspicion of CDI. Formed stool should never be tested, and testing should never be used as a test of cure. The preferred two-step algorithm begins with glutamate dehydrogenase (GDH) antigen screening, which is highly sensitive (95 to 100%) and detects the C. difficile organism regardless of toxin production. If GDH is positive, confirmatory testing with toxin enzyme immunoassay for toxin A and B is performed, which has a sensitivity of 75 to 85% and specificity above 95%. When results are discordant (GDH positive, toxin EIA negative), reflex testing with nucleic acid amplification testing (PCR) for the tcdB gene is performed.

NAAT used alone has high sensitivity (95 to 99%) but detects the toxin gene rather than free toxin, meaning it cannot distinguish active infection from colonization. It should only be used in patients with high pretest probability, not as a screening tool. Toxin EIA alone has insufficient sensitivity and is not recommended as a standalone test.

Important Testing Principles

Key testing principles include never testing asymptomatic patients (which yields a high false-positive rate with NAAT), never performing a test of cure (as shedding persists for weeks after successful treatment), and not repeating testing within 7 days of a negative result (which has sensitivity above 99% for true negatives). Laxative use should prompt holding the laxative and reassessing stool consistency before testing.

<image>A two-step diagnostic algorithm for C. difficile testing. Start with "Clinical suspicion: >=3 unformed stools/24 hours + risk factors." First step: "GDH Antigen Screen." If negative: "CDI unlikely — consider alternative diagnoses." If positive: "Toxin EIA (A/B)." If toxin positive: "CDI CONFIRMED — treat based on severity." If toxin negative: "Discordant result — perform NAAT/PCR for tcdB gene." If NAAT positive: "Toxigenic C. difficile present — clinical correlation required (may be colonization vs. infection); treat if clinical suspicion high." If NAAT negative: "CDI excluded." Include a warning box: "Do NOT test: formed stool, asymptomatic patients, test of cure, repeat within 7 days." Add sensitivity/specificity values next to each test: GDH (sens 95-100%, spec 85-95%), Toxin EIA (sens 75-85%, spec >95%), NAAT (sens 95-99%, spec 95-99%). Use traffic light colors: green for negative/excluded, red for confirmed, yellow for discordant requiring further workup.</image>

Treatment

Non-Severe, Initial Episode

Fidaxomicin at 200 mg orally twice daily for 10 days is the preferred first-line therapy according to ACG 2021 and IDSA 2021 guidelines. This narrow-spectrum macrolide causes minimal microbiome disruption. The MODIFY I and II trials demonstrated that fidaxomicin was non-inferior to vancomycin for initial cure and was superior for sustained clinical cure, with significantly fewer recurrences (13% versus 27%). The EXTEND trial demonstrated that an extended-pulsed regimen (200 mg twice daily on days 1 through 5, then 200 mg once daily on alternate days from days 7 through 25) further reduced recurrence to 4% compared to 17% with standard vancomycin. Oral vancomycin at 125 mg four times daily for 10 days is an acceptable alternative first-line agent. Metronidazole at 500 mg orally three times daily for 10 days is no longer recommended for initial treatment in adults due to inferior cure rates (73% versus 81% for vancomycin) and should only be used when fidaxomicin and vancomycin are unavailable.

Severe CDI

Severe CDI should be treated with fidaxomicin 200 mg twice daily for 10 days (preferred) or oral vancomycin 125 mg four times daily for 10 days, with close monitoring for progression to fulminant disease.

Fulminant CDI

Fulminant CDI requires a multimodal approach. Oral vancomycin is escalated to 500 mg four times daily via the oral or nasogastric route. Intravenous metronidazole at 500 mg every 8 hours is added as the only antibiotic with evidence supporting the intravenous route in CDI, achieving colonic concentrations through biliary excretion and secretion across inflamed colonic mucosa. In the presence of ileus or colonic distension, rectal vancomycin enemas (500 mg in 100 mL of normal saline every 6 hours via rectal tube) are added. Surgical consultation should be obtained early for all patients with fulminant CDI. Subtotal colectomy with end ileostomy is the traditional surgical approach, carrying a mortality of 30 to 50%. Diverting loop ileostomy with colonic lavage, the Zuckerbraun approach using antegrade vancomycin washout, represents an alternative with lower mortality in case series. Indications for surgery include perforation, toxic megacolon not responding to medical therapy, multiorgan failure, refractory shock, white blood cell count exceeding 50,000, and lactate above 5.

Recurrent CDI

First Recurrence

For the first recurrence, fidaxomicin using either the standard or extended-pulsed regimen is preferred. Oral vancomycin given as a taper and pulse is an alternative: 125 mg four times daily for 14 days, then 125 mg twice daily for 7 days, then 125 mg daily for 7 days, then 125 mg every 2 to 3 days for 2 to 8 weeks. Bezlotoxumab, a monoclonal antibody targeting toxin B, is administered as a single 10 mg/kg intravenous dose during CDI antibiotic treatment. The MODIFY trials demonstrated that it reduced recurrence from 28% to 17%, yielding a number needed to treat of 10. It is approved for prevention of recurrence in high-risk patients, including those over 65, the immunocompromised, those with severe CDI, and those infected with the NAP1/BI/027 strain. A heart failure warning applies, as higher rates of heart failure were observed in patients with pre-existing congestive heart failure.

Second or Subsequent Recurrence

Fecal microbiota transplantation is the gold standard for multiply recurrent CDI, achieving cure rates of 85 to 90% for recurrent disease. The landmark van Nood trial demonstrated 94% efficacy compared to 31% with vancomycin alone. FMT can be administered via colonoscopy (preferred for the first procedure), upper endoscopy or nasogastric tube, enema, or capsules, with comprehensive donor screening for pathogens required. Two FDA-approved microbiome-based therapies now offer standardized alternatives: fecal microbiota live-jslm (Rebyota/RBL), administered rectally as a single dose after vancomycin, with the PUNCH CD3 trial demonstrating 70.6% versus 57.5% placebo success; and fecal microbiota spores live-brpk (Vowst/SER-109), administered as oral capsules (4 capsules daily for 3 days), with the ECOSPOR III trial showing 88% versus 60% placebo recurrence-free rates at 8 weeks. An alternative approach is a vancomycin taper followed by a rifaximin chaser (vancomycin 125 mg four times daily for 14 days, then rifaximin 400 mg three times daily for 20 days).

Special Populations

CDI in IBD

Patients with IBD have a higher incidence of CDI, higher recurrence rates, and worse outcomes including increased colectomy and mortality. CDI testing should be performed during all IBD flares, even in patients on immunosuppression. Standard CDI therapy should be administered, and IBD immunosuppression should be continued when possible, with a steroid taper preferred over initiation of new steroids. FMT appears safe and effective in IBD patients with recurrent CDI. NAAT-positive, toxin-negative results are more challenging to interpret in this population and require careful clinical judgment.

CDI in Pregnancy

Oral vancomycin is the preferred agent in pregnancy due to its minimal systemic absorption. Fidaxomicin has limited safety data and is generally avoided. Metronidazole should be avoided in the first trimester due to potential teratogenicity.

Prevention

Infection Control

Contact precautions with gown and gloves for all patient contact are mandatory. Hand hygiene must be performed with soap and water, as alcohol-based hand sanitizers are ineffective against C. difficile spores. Environmental cleaning requires bleach-based (sodium hypochlorite) or sporicidal agents. Antimicrobial stewardship, particularly restriction of fluoroquinolones and clindamycin, is essential.

Antibiotic Stewardship

Antibiotic stewardship is the single most impactful intervention for CDI prevention. Fluoroquinolone restriction programs have demonstrated 50 to 70% reductions in CDI incidence.

<image>A treatment pathway diagram for C. difficile infection by severity and recurrence. Organized as a grid with rows for "Initial Episode" and "Recurrence (1st, 2nd+)" and columns for "Non-Severe," "Severe," and "Fulminant." Non-Severe Initial: Fidaxomicin 200 mg BID x 10 days (preferred) or PO vancomycin 125 mg QID x 10 days. Severe Initial: Fidaxomicin 200 mg BID x 10 days or PO vancomycin 125 mg QID x 10 days. Fulminant: PO vancomycin 500 mg QID + IV metronidazole 500 mg q8h +/- rectal vancomycin enemas; surgical consultation. 1st Recurrence: Fidaxomicin extended-pulsed regimen or vancomycin taper/pulse +/- bezlotoxumab. 2nd+ Recurrence: FMT (colonoscopic or FDA-approved products: Rebyota or Vowst) after standard antibiotic course. Include a "Prevention" footer: antibiotic stewardship, contact precautions, soap/water hand hygiene, sporicidal cleaning. Color code: green for preferred, yellow for alternative, red for fulminant/surgical. Include cure rates and recurrence rates next to each regimen.</image>

Key Clinical Pearls

• Fidaxomicin is now the preferred first-line therapy for initial and recurrent CDI due to superior sustained cure rates and fewer recurrences (MODIFY and EXTEND trials)
• Do NOT test asymptomatic patients, formed stool, or use NAAT as a screening test — leads to overdiagnosis and unnecessary treatment of colonization
• Metronidazole is NO longer recommended as first-line for CDI in adults — inferior cure rates vs vancomycin and fidaxomicin
• Fulminant CDI may present with ileus and ABSENCE of diarrhea — maintain high clinical suspicion in critically ill patients with leukocytosis and abdominal distension
• Bezlotoxumab reduces recurrence by 10-11% (NNT = 10) in high-risk patients — consider for elderly, immunocompromised, and those with prior CDI episodes
• FDA-approved microbiome-based therapies (Rebyota, Vowst) provide standardized alternatives to donor-dependent FMT
• Always test for CDI during IBD flares — concomitant infection is common and alters management
• Soap and water handwashing is mandatory (alcohol-based hand sanitizers do NOT kill C. difficile spores)

References

1. Johnson S, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029-e1044.
2. Kelly CR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124-1147.
3. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection (MODIFY I/MODIFY II). N Engl J Med. 2011;364(5):422-431.
4. Feuerstadt P, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220-229.
5. van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.

Read this lecture as Markdown